Mixed reality moves into the enterprise mainstream

Tern plc

A new phase of computing is taking shape as artificial intelligence and mixed reality converge. The shift from virtual to spatial computing marks the point where digital content no longer replaces reality but enhances it, and this time the technology is ready to scale.

Over the past ten years, immersive devices have moved through several hype cycles. Oculus, Vive, and Meta each pushed boundaries, but adoption stalled outside specialist sectors. Apple changed that dynamic with the launch of Vision Pro, positioning mixed reality as a serious computing platform rather than an entertainment accessory.

In parallel, AI has embedded itself across business software, creating intelligent systems that learn, predict, and respond to human needs. The merging of these two technologies is transformative. Mixed reality now has access to real-time understanding through AI, allowing devices to see, hear, and act on context. As hardware becomes lighter and socially acceptable, mixed reality glasses are set to evolve into all-day wearables that deliver live guidance, data access, and communication.

Meta’s display glasses with gesture control, Samsung and Google’s Moohan headset with Gemini AI, Amazon’s Jayhawk smart glasses for employees, and Apple’s Vision Air all signal a shared destination. By 2028, these devices will move into everyday enterprise use.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search